Journal article · 2023 · Open access

Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study

Prasad Suryakant Kulkarni, Abhijit Kadam, Sheela Godbole, Varsha Rajat Bhatt, Abhishek V. Raut, Sunil Kohli, Santanu Kumar Tripathi, Praveen Kulkarni, Rakhi Ludam, Madhav Prabhu, Ashish Bavdekar, Nithya Gogtay and 71 more

The Lancet Regional Health - Southeast Asia, 10, 100139 · Published 11 January 2023 · DOI 10.1016/j.lansea.2022.100139

Open full textCite this paper

In brief

“Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study” is a 2023 journal article by Prasad Suryakant Kulkarni and 82 co-authors, published in The Lancet Regional Health - Southeast Asia. OpenAlex counts 13 citations as of 20 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at The Lancet Regional Health - Southeast Asia.

Citations
13
Most cited in
2024 (6)
Field-weighted impact
2.04
References
30
Authors
83

Abstract

NVX-CoV2373, a Covid-19 vaccine was developed in the USA with ∼90% efficacy. The same vaccine is manufactured in India after technology transfer (called as SII-NVX-CoV2373), was evaluated in this phase 2/3 immuno-bridging study. This was an observer-blind, randomised, phase 2/3 study in 1600 adults. In phase 2, 200 participants were randomized 3:1 to SII-NVX-CoV2373 or placebo. In phase 3, 1400 participants were randomized 3:1 to SII-NVX-CoV2373 or NVX-CoV2373 (940 safety cohort and 460 immunogenicity cohort). Two doses of study products (SII-NVX-CoV2373, NVX-CoV2373 or placebo) were given 3 weeks apart. Primary objectives were to demonstrate non-inferiority of SII-NVX-CoV2373 to NVX-CoV2373 in terms of geometric mean ELISA units (GMEU) ratio of anti-S IgG antibodies 14 days after the second dose (day 36) and to determine the incidence of causally related serious adverse events (SAEs) through 180 days after the first dose. Anti-S IgG response was assessed using an Enzyme-Linked Immunosorbent Assay (ELISA) and neutralizing antibodies (nAb) were assessed by a microneutralization assay using wild type SARS CoV-2 in participants from the immunogenicity cohort at baseline, day 22, day 36 and day 180. Cell mediated immune (CMI) response was assessed in a subset of 28 participants from immunogenicity cohort by ELISpot assay at baseline, day 36 and day 180. The total follow-up was for 6 months. Trial registration: CTRI/2021/02/031554. Total 1596 participants (200 in Phase 2 and 1396 in Phase 3) received the first dose. SII-NVX-CoV2373 was found non-inferior to NVX-CoV2373 (anti-S IgG antibodies GMEU ratio 0.91; 95% CI: 0.79, 1.06). At day 36, there was more than 58-fold rise in anti-S IgG and nAb titers compared to baseline in both the groups. On day 180 visit, these antibody titers declined to levels slightly lower than those after the first dose (13–22 fold-rise above baseline). Incidence of unsolicited and solicited AEs was similar between the SII-NVX-CoV2373 and NVX-CoV2373 groups. No adverse event of special interest (AESI) was reported. No causally related SAE was reported. SII-NVX-CoV2373 induced a non-inferior immune response compared to NVX-CoV2373 and has acceptable safety profile. SIIPL, Indian Council of Medical Research, Novavax.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Kulkarni, P. S., Kadam, A., Godbole, S., Bhatt, V. R., Raut, A. V., Kohli, S., Tripathi, S. K., Kulkarni, P., Ludam, R., Prabhu, M., Bavdekar, A., Gogtay, N., Meshram, S., Kadhiravan, T., Kar, S., Narayana, D. A., Samuel, C., Kulkarni, G., Gaidhane, A. M., . . . Salvi, S. (2023). Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study. The Lancet Regional Health - Southeast Asia, 10, 100139. https://doi.org/10.1016/j.lansea.2022.100139

MLA 9

Kulkarni, Prasad Suryakant, et al. “Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study.” The Lancet Regional Health - Southeast Asia, vol. 10, 2023, p. 100139. https://doi.org/10.1016/j.lansea.2022.100139.

Chicago

Kulkarni, Prasad Suryakant, Abhijit Kadam, Sheela Godbole, Varsha Rajat Bhatt, Abhishek V. Raut, Sunil Kohli, Santanu Kumar Tripathi, et al. 2023. “Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study.” The Lancet Regional Health - Southeast Asia 10: 100139. https://doi.org/10.1016/j.lansea.2022.100139.

Harvard

Kulkarni, P. S. et al. (2023) ‘Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study’, The Lancet Regional Health - Southeast Asia, 10, p. 100139. doi:10.1016/j.lansea.2022.100139.

IEEE

P. S. Kulkarni et al., “Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study,” The Lancet Regional Health - Southeast Asia, vol. 10, p. 100139, 2023, doi: 10.1016/j.lansea.2022.100139.

BibTeX

@article{kulkarni2023safety,
  title     = {{Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study}},
  author    = {Kulkarni, Prasad Suryakant and Kadam, Abhijit and Godbole, Sheela and Bhatt, Varsha Rajat and Raut, Abhishek V. and Kohli, Sunil and Tripathi, Santanu Kumar and Kulkarni, Praveen and Ludam, Rakhi and Prabhu, Madhav and Bavdekar, Ashish and Gogtay, Nithya and Meshram, Sushant and Kadhiravan, Tamilarasu and Kar, Sonali and Narayana, D.H. Ashwath and Samuel, Clarence and Kulkarni, Govind and Gaidhane, Abhay Motiramji and Sathyapalan, Dipu T and Raut, Sidram K. and Hadda, Vijay and Bhalla, Hira Lal and Bhamare, Chetanraj and Dharmadhikari, Abhijeet and Plested, Joyce S. and Cloney-Clark, Shane and Zhu, Mingzhu and Pryor, Melinda and Hamilton, Stephanie and others},
  journal   = {The Lancet Regional Health - Southeast Asia},
  year      = {2023},
  volume    = {10},
  pages     = {100139},
  doi       = {10.1016/j.lansea.2022.100139},
  url       = {https://doi.org/10.1016/j.lansea.2022.100139}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202211
202344
202466
202511
202611

Its field-weighted citation impact is 2.04: it has been cited 2.04 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research

  • NVX-CoV2373
  • COVID-19 vaccines
  • SARS-CoV-2
  • vaccine safety
  • immunogenicity
  • neutralizing antibodies
  • cell-mediated immunity
  • serious adverse events

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Kulkarni, P. S., Kadam, A., Godbole, S., Bhatt, V. R., Raut, A. V., Kohli, S., Tripathi, S. K., Kulkarni, P., Ludam, R., Prabhu, M., Bavdekar, A., Gogtay, N., Meshram, S., Kadhiravan, T., Kar, S., Narayana, D. A., Samuel, C., Kulkarni, G., Gaidhane, A. M., . . . Salvi, S. (2023). Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study. The Lancet Regional Health - Southeast Asia, 10, 100139. https://doi.org/10.1016/j.lansea.2022.100139

How many times has this paper been cited?

13 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at The Lancet Regional Health - Southeast Asia: sign in and open the full text from this page.

Who wrote this paper?

Prasad Suryakant Kulkarni, Abhijit Kadam, Sheela Godbole, Varsha Rajat Bhatt, Abhishek V. Raut, Sunil Kohli, Santanu Kumar Tripathi, Praveen Kulkarni, Rakhi Ludam, Madhav Prabhu, Ashish Bavdekar, Nithya Gogtay and 71 more.

What is the DOI of this paper?

10.1016/j.lansea.2022.100139, permanently at https://doi.org/10.1016/j.lansea.2022.100139. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.